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Abstract
Introduction: New antiretroviral agents that are more convenient, better tolerated with fewer short- and long-term side effects, and that
have novel resistance patterns are needed at all lines of therapy in patients infected with human immunodeficiency virus (HIV). Therefore,
next generation products of current classes and alternative classes of antiretroviral agents are needed. The CC-chemokine receptor 5
(CCR5) antagonists are a novel class of antiretroviral agents that prevent the entry of HIV into host cells by blocking the CCR5 coreceptor.
Within this class, maraviroc is the agent furthest along in development.
Aims: The aim of this review is to evaluate the emerging evidence for the use of the CCR5 antagonist maraviroc in antiretroviral
treatment-naïve and treatment-experienced patients with HIV-1 infection.
Evidence review: Preliminary evidence from phase I/IIa short-term studies suggest that maraviroc monotherapy is effective at reducing
HIV viral load, and is generally well tolerated. In-vitro evidence suggests that maraviroc will be effective in drug-naïve patients with
CCR5-tropic virus, as well as in those with CCR5-tropic virus who have developed HIV resistance to existing antiretroviral regimens.
However, it is not known how quickly resistance may develop to maraviroc in clinical practice. 
Clinical potential: Current evidence supports the continued development of maraviroc as a potentially useful, alternative treatment for
the management of HIV infection. Maraviroc monotherapy has a high potency and long half-life, allowing single-pill dosing. Therefore, 
it is expected that maraviroc will have a beneficial effect on patient adherence and viral load in combination with other antiretroviral
agents. Maraviroc is only effective against CCR5-tropic virus, which predominates throughout infection but is more common in patients
at the early asymptomatic stage of infection.
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Core evidence proof of concept summary for maraviroc in HIV infection
Outcome measure Emerging evidence
Disease-oriented evidence
HIV viral load Mean maximum viral load reduction between 1.6 and 1.84 log10 copies/mL after 10 days of monotherapy with 
maraviroc at clinical doses
Rebound of viral load Delay in viral rebound after discontinuation of maraviroc monotherapy 
Selectivity Maraviroc selectively binds to CCR5, causing an allosteric change, and preventing R5 HIV from entering CD4 cells 
Resistance In vitro, maraviroc is effective against HIV variants resistant to existing antiretroviral agents. Preliminary evidence of CD4
cell increases in dual-tropic patients. Further confirmation is required
Patient-oriented evidence
Tolerability Maraviroc is well tolerated in short-term studies, with a similar tolerability to placebo
Cardiovascular effects No evidence of prolongation of QTc interval. Postural hypotension at unit doses ≥600 mg
Liver toxicity One case of serious hepatotoxicity reported. The DSMB considered this case highly unlikely to be related to maraviroc
treatment, but could not rule out a contribution by maraviroc. Phase III data are required to fully assess hepatotoxicity
Drug interactions Maraviroc is metabolized by CYP3A4 and is a substrate for Pgp. Dose adjustments are required when administered
concomitantly with potent CYP3A4 inhibitors or inducers
CCR5, CC-chemokine receptor 5; CYP3A4, cytochrome P450 3A4; DSMB, Data Safety Monitoring Board; HIV, human immunodeficiency virus; Pgp, P-glycoprotein; R5 HIV, HIV that only 
uses the CCR5 receptor.Scope, aims, and objectives
Maraviroc (UK-427,857; Pfizer) is a CC-chemokine receptor 5
(CCR5)-receptor antagonist in development for the treatment of
human immunodeficiency virus (HIV) infection. It is currently being
evaluated in phase IIb/III trials in adults with HIV-1 infection. The
objective of this article is to review the preclinical and early clinical
development evidence for the effectiveness of maraviroc against
HIV-1 infection, and to assess its therapeutic potential.
Methods
English language medical literature databases were searched for
appropriate articles related to the treatment of HIV infection with
maraviroc. The searches were conducted on May 16, 2006 using
the search terms “maraviroc OR UK-427,857.” The cut-off date
was from the beginning of the database to the date of the search
unless otherwise stated. 
• PubMed, http://www.ncbi.nlm.nih.gov
• EMBASE, http://www.datastarweb.com
• BIOSIS, http://www.datastarweb.com
• Database of Abstracts of Reviews of Effects (DARE),
http://www.york.ac.uk/inst/crd/crddatabases.htm
• Cochrane Database of Systematic Reviews (CDSR),
http://www.cochrane.org/index0.htm
• Public Library of Science,
http://www.plos.org/journals/index.html
• Clinical Evidence (BMJ), http://www.clinicalevidence.com
• Clinical trial registers http://www.clinicaltrials.gov, and
http://www.clinicalstudyresults.org
• National Institute for Health and Clinical Excellence (NICE),
http://www.nice.org.uk
• National Guideline Clearinghouse, http://www.guideline.gov
After removal of duplicates, a total of 28 records were retrieved
from PubMed and EMBASE; no additional citations were identified
from the other databases (Table 1). Records were manually
reviewed and 22 citations were excluded: nonsystematic reviews
(n=3), and citations that mentioned maraviroc but did not
investigate its preclinical or clinical use (n=19). No systematic
reviews of maraviroc have been published. ClinicalTrials.gov
identified four ongoing phase IIb/III clinical trials. Guidelines for
the treatment of HIV were identified from the website of the British
HIV Association (http://www.bhiva.org) and the AIDSinfo website
(http://AIDSinfo.nih.gov).
Online abstracts from the following congresses were searched
using the search strategy “maraviroc OR UK-427,857”, or were
hand-searched:
• XV International AIDS Society (IAS) Conference, all
conferences from 2001 to 2005, http://www.iasociety.org
• XVI International HIV Drug Resistance Workshop 2005,
http://www.intmedpress.com/General/showSectionSub.cfm?S
ectionID=2&SectionSubID=1&SectionSubSubID=1
• 10th–13th Conferences on Retroviruses and Opportunistic
Infections (CROI), 2003–2006, http://www.retroconference.org
• 5th International Workshop on Clinical Pharmacology of HIV
Therapy, 2004
• 7th International Congress on Drug Therapy in HIV Infection,
2004
• 10th European AIDS Conference, 2005
• Interscience Conference on Antimicrobial Agents and
Chemotherapy (ICAAC), all conferences from 2003 to 2005
A total of 21 abstracts were identified (Table 1). Among the
relevant abstracts, six reported on the outcomes of preclinical
studies, ten on the pharmacokinetics of maraviroc, and five on
clinical data. 
The searches on PubMed and IAS were updated on October 2,
2006. Two new records were identified, one of which was
included in the review.
Disease overview
The AIDS epidemic
Despite advances in the antiretroviral treatment of HIV infection,
the acquired immune deficiency syndrome (AIDS) epidemic
claimed 3.1 million lives in 2005 (UNAIDS/WHO 2005). It is
estimated that 40.3 million people worldwide are now living with
HIV, and that approximately five million people were newly
infected with the virus in 2005. 
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Category Number of records
Full papers Abstracts
Initial search 28 21
records excluded 22 0
records included 6 21
Search update, new records 1 1
records excluded 1 0
records included 0 1
Level 2 clinical evidence (RCT) 1 1
For definition of levels of evidence, see Editorial Information on inside back cover.
RCT, randomized controlled trial.
Table 1 | Evidence base included in the review3
Pathophysiology of HIV infection
HIV infects and destroys CD4-positive cells during the process 
of replication. As the virus continues to replicate, CD4-positive 
T cells are progressively depleted which leads to the onset of
immunodeficiency, i.e. AIDS. When AIDS develops, the individual
becomes vulnerable to opportunistic infections and rare
malignancies such as pneumocystis carinii, cytomegalovirus, and
Kaposi's sarcoma.
The HIV lifecycle 
The initial step in the HIV-1 lifecycle is viral attachment to the
CD4-positive T-cell surface, followed by viral entry. This process
involves the viral envelope protein (Env), which undergoes
receptor-induced conformational changes and thereby mediates
fusion between the viral and cellular membranes (Moore & Doms
2003; Fig. 1). 
Env consists of a glycoprotein (gp) 120 subunit which binds to the
cell surface CD4-positive receptor and induces a conformational
change in gp120, exposing the coreceptor binding site in the 
V3 region of gp120. This site binds to one of the chemokine
coreceptors, CCR5 (Deng et al. 1996; Dragic et al. 1996) or CXCR4
(Feng et al. 1996) and induces an additional conformational
change in the Env transmembrane protein gp41, which leads to
the insertion of its N-terminal fusion peptide into the target cell
membrane. A triple-stranded coiled coil is formed by three HR1
domains from the N-terminal helical regions of each of the three
gp41 ectodomains. The gp41 subunit then folds back on itself to
allow the C-terminal helical region (HR2) to pack into grooves on
the outside of HR1 to form a six-helical bundle formation.
Consequently, the virus and cell membranes are brought into
close proximity to initiate fusion and ultimately entry of the viral
core into the target cell.
Once internalized, the virus is uncoated releasing genomic RNA
and reverse transcriptase into the cytoplasm. Reverse
transcriptase synthesizes a DNA copy of the single-stranded 
viral RNA. This is then integrated randomly into the host’s
chromosomal DNA by viral integrase (Chow et al. 1992). The
provirus remains dormant until the cell is activated (Fauci 1988).
Upon cell activation, the proviral DNA is transcribed into viral
genomic RNA and viral mRNA by cellular enzymes. Subsequently,
viral mRNA is translated into viral proteins. The enzyme HIV
protease mediates the modification and assembly of these
proteins into a mature, infectious virion. The virus particle is then
released by budding from the cell membrane (Ho et al. 1987;
Debouck 1992). 
HIV-1 variants
HIV-1 variants differ in their use of coreceptors for entry. Variants
may exclusively use the CCR5 coreceptor (CCR5-tropic or R5
viruses) or exclusively use the CXCR4 coreceptor (CXCR4-tropic
or X4 viruses). Those variants that use either receptor (i.e. a mixture 
of R5 and X4 virus) are termed dual tropic or R5X4 viruses. 
The CCR5-tropic virus predominates in patients throughout infection.
At the early asymptomatic stage of infection approximately 85% of
patients are infected with HIV that only uses the CCR5 receptor (R5
HIV). The CXCR4-utilizing virus (X4 HIV) generally emerges with
time and with CD4 depletion, with X4 virus detectable in
approximately 50% of treatment-experienced patients (Philpott
2003; Brumme et al. 2005; Moyle et al. 2005; Hunt et al. 2006;
Wilkin et al. 2006). The appearance of X4 HIV has been associated
with rapid CD4 decline and disease progression, but 
it is unclear whether the emergence of X4 HIV is the cause or 
the effect (Koot et al. 1999; Moore et al. 2004; Troyer et al. 2005).
Current therapy options
Currently, eradication of HIV infection cannot be achieved with
existing regimens. Therefore, the goals of therapy are the
prolonged suppression of viral levels to less than detection limits
(<50 copies/mL for Amplicor assay, <75 copies/mL for VERSANT
assay, and <80 copies/mL for NucliSens assay), with the aim to
restore and preserve immunologic function, improve quality of life,
and avoid HIV-associated morbidity and mortality (Gazzard 2005;
DHSS 2006).
The host cells’ involvement in many stages of the virus lifecycle is a
significant obstacle in the selective inhibition of viral replication
without damage to the host. There are currently several classes of
antiretroviral drugs available which may be used to target different
stages of the HIV lifecycle, where replication may be prevented by
selectively targeting the virus. Nucleoside/nucleotide reverse
transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase
inhibitors (NNRTIs), and protease inhibitors (PIs) act on intracellular
viral targets, and entry/fusion inhibitors act on viral proteins to
prevent viral fusion and thereby prevent virus entry into cells 
(Table 2). A combination of three or more drugs from these different
classes (generally containing an NNRTI plus two NNRTIs, or a
boosted PI and two NRTIs) is commonly known as highly active
antiretroviral therapy (HAART).
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Fig. 1 | The mechanism of HIV-1 entry and fusion targets for
inhibition (adapted from Moore JP, Doms RW. The entry
of entry inhibitors: a fusion of science and medicine.
PNAS. 2003;100:10598–10602. Copyright 2003 National
Academy of Sciences, USA)A comprehensive review of all current therapy options for the
treatment of HIV is beyond the scope of this article. However, to
aid the understanding of the mechanism of action and
development of maraviroc, a review of the entry inhibitors,
primarily the CCR5 antagonists, are summarized below. HIV entry
inhibitors can be classified into three distinct classes, each
targeting one of the three steps in the entry process: CD4 binding
inhibitors, CCR5/CXCR4 coreceptor antagonists, and fusion
inhibitors (Fig. 1). 
CD4 binding inhibitors
There are several compounds in development that inhibit the
initial interaction between gp120 and the CD4 receptor. Those
most advanced in development include a soluble antibody-like
fusion protein, PRO 542 (Progenics Pharmaceuticals Inc.); a CD4-
specific monoclonal antibody, TNX-355 (Tanox Inc.); and a small
molecule inhibitor, BMS-806 (Bristol-Myers Squibb). 
CCR5 antagonists
Individuals who lack a functional CCR5 gene are highly resistant
to HIV-1 infection, and patients with only one copy of a functional
CCR5 gene demonstrate delayed CD4 depletion and slower
progress to AIDS and death (Liu et al. 1996; Samson et al. 1996;
Moore et al. 2004). Therefore, the CCR5 coreceptor is a novel
target for prevention of HIV replication and disease progression.
CCR5 antagonists inhibit virus entry by binding to a host cell
protein, the CCR5 receptor, and inducing an allosteric change
which renders the molecule unrecognizable to wild type R5 HIV.
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Table 2 | Antiretroviral agents currently licensed for the treatment of HIV-1 infection
Class and mechanism of action Drug
Reverse transcriptase inhibitors (RTIs)
Inhibit reverse transcription of the viral RNA into double-stranded DNA by the viral
enzyme reverse transcriptase
Nucleoside RTIs (NRTIs)
Retrovir® (zidovudine) 
Hivid® (zalcitabine)a
Epivir® (lamivudine) 
Videx® (didanosine) 
Zerit® (stavudine)
Ziagen® (abacavir) 
Viread® (tenofovir)
Emtriva® (emtricitabine)
Combivir® (zidovudine + lamivudine)
Epzicom® (USA) / Kivexa® (UK) (abacavir + lamivudine)
Truvada® (tenofovir + emtricitabine)
Trizivir® (abacavir + zidovudine + lamivudine)
Nonnucleoside RTIs (NNRTIs)
Viramune® (nevirapine)
Rescriptor® (delavirdine)a
Sustiva® (efavirenz)
Protease inhibitors (PIs)
Inhibits the HIV protease enzyme which is required to cleave the polyprotein
products of the gag and gag-pol genes into functional core proteins and viral
enzymes. Inhibition results in the production of immature virus
Invirase® (saquinavir hard-gel capsule)
Fortovase® (saquinavir soft-gel capsule)
Norvir® (ritonavir)
Viracept® (nelfinavir)
Crixivan® (indinavir)
Agenerase® (amprenavir)
Reyataz® (atazanavir)
Lexiva® (USA) / Telzir® (UK) (fosamprenavir)
Aptivus® (tipranavir)
Kaletra® (lopinavir + ritonavir)
Entry inhibitors
Enfuvirtide is a peptide based on the sequence of the HR2 region. It binds to 
the triple-stranded coiled coil formed by the three HR1 domains, preventing the
formation of the six-helix bundle, and hence inhibiting membrane fusion with 
the cellular target (Chen et al. 1995)
Fuzeon™ (enfuvirtide; T-20) 
aCurrently unlicensed in the UK.5
Initially, five small, orally available CCR5 antagonists were in clinical
development; SCH-C (SCH-351125; Schering-Plough); TAK-779
(Takeda Chemical Industries Ltd), aplaviroc (GlaxoSmithKline),
vicriviroc (SCH-417690; Schering-Plough), and maraviroc (Pfizer)
(Table 3). However, only two remain with maraviroc being the furthest
along in clinical development. Vicriviroc is in phase II for treatment-
experienced patients. AnorMED Inc. currently has multiple lead
candidates in preclinical testing including AMD887, and plans to
select a lead candidate for clinical studies in 2006 (Anon. 2006a).
CXCR4 antagonists are also in development. The CXCR4
antagonist (AnorMED Inc.) has been shown to strongly inhibit viral
infection by CXCR4-tropic virus in vitro (Schols et al. 2003).
However, a safety trial with AMD070 in HIV-infected patients has
been suspended (Anon. 2006b).
Fusion inhibitors
Currently, there is only one licensed fusion inhibitor—enfuvirtide
(Fuzeon™, T-20; Trimeris Inc., Roche Laboratories) which is
administered by subcutaneous injection (90 mg twice daily). It was
approved in 2003 for use in combination with other antiretroviral
agents in treatment-experienced patients with evidence of HIV-1
replication despite ongoing antiretroviral therapy. 
A second-generation fusion inhibitor, tifuvirtide (T1249; Trimeris
Inc.), has been developed which is more potent against HIV than
enfuvirtide. However, formulation difficulties have halted its
clinical development. Two additional next-generation fusion
inhibitors are also in early-stage development by Trimeris and
Roche, TRI-1144 and TRI-999. Preclinical data have reported that
these peptides have potent antiviral activity and durable control of
HIV replication in vitro (Delmedico et al. 2006).
Unmet needs
The benefits of HAART in the treatment of HIV-1 infection are well
documented. Over the past 8 years, HAART regimens have been
successful in dramatically reducing plasma viral load, delaying
disease progression to AIDS, increasing CD4 cell counts,
improving quality of life, and prolonging survival (Palella et al.
1998). However, several studies have shown that HAART
regimens are not durable, and patients eventually experience
virologic failure. 
The advantages and disadvantages of regimens for treatment-
naïve patients preferred by recent US [Department of Health and
Human Services (DHSS)] and British HIV Association (BHIVA)
guidelines are indicated in Table 4 (Gazzard 2005; DHSS 2006). 
In patients experiencing virologic failure, these guidelines
recommend determining factors which are affecting the plasma
drug levels (e.g. poor adherence, intolerability, drug interactions).
If the drug exposure is optimal, it is suggested that resistance
testing may be performed and that the treatment regimen is
augmented/changed. 
However, the HIV Outpatients Study (HOPS) demonstrated that
sequential HAART regimens were progressively less durable and
many patients exhausted viable antiretroviral treatment options
either due to resistance/cross-resistance or tolerability issues
(Palella et al. 2002). Patients derived less benefit (i.e. reduced viral
suppression) from successive, increasingly complex, and expensive
salvage regimens which were often more difficult to tolerate. 
An observational, longitudinal study demonstrated that 6 years
after starting HAART, approximately 20% of treatment-
experienced patients and 10% of treatment-naïve patients were
estimated to have triple drug-class failure (TCF) (Mocroft et al.
2004). In addition, it has been shown that approximately 20–40%
of treatment-naïve patients experience virologic failure within 
2–3 years of starting their first HAART regimen (Gullick et al. 2000;
Kaufmann et al. 2000; Le Moing et al. 2002; Phillips et al. 2002).
There are several factors that may limit the success of HAART
including drug resistance, patient adherence, drug tolerability and
toxicity, and drug interactions. Other factors which may influence
success include the cost of therapy, and the presence of
comorbid conditions such as substance abuse and addiction.
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CCR5 antagonist Manufacturer Status
Maraviroc (UK-427,857) Pfizer  Phase IIb/III (see text for details)
Vicriviroc maleate (SCH-D; SCH-417690)
Piperazine-based antagonist
Schering-Plough Phase II
Incidence of five cases of cancer (four lymphoma, one stomach adenocarcinoma)
reported in 118 patients in one phase II trial (March 2006)
Development for treatment-naïve patients was discontinued due to poor efficacy
(Anon. 2005c)
SCH-C (SCH-351125) Schering-Plough Discontinued due to an unacceptable side-effect profile (effect on QT interval)
Aplaviroc hydrochloride (ONO-4128; 
GW-873140)
Spirodike-topiperazine-based antagonist
GlaxoSmithKline Discontinued after cases of hepatotoxicity were reported in phase II and phase III
trials (Anon. 2005d)
TAK-652 Takeda Chemical Industries Ltd Under consideration for development
TAK-779 lacked oral bioavailability and is no longer in clinical development
Table 3 | Clinical development of CCR5 antagonists: current status (May 2006)Maraviroc | proof of concept review
© 2007 Core Medical Publishing Limited 6
Preferred regimen Components Advantages Disadvantages
NNRTI-based regimen Efavirenz  Efavirenz advantages: 
Potent antiretroviral activity
Availability of long-term efficacy data
Low pill burden and frequency (one tablet 
per day)
NNRTI class advantages:
Save PI options for later use
Less dyslipidemia or fat distribution than 
PI-based regimens
Efavirenz disadvantages:
Neuropsychiatric side effects
Teratogenic in nonhuman primates,
contraindicated in first trimester of pregnancy
and avoid use in women with potential for
pregnancy
NNRTI class disadvantages: 
Low genetic barrier to resistance
Cross-resistance among NNRTIs
Skin rash
Potential for CYP450 drug interactions
+ lamivudine or emtricitabine
+ zidovudine or tenofovir
Zidovudine + lamivudinea advantages:
Extensive and favorable virologic experience
Ease of dosing (coformulation)
No food effect
Lamivudine has minimal side effects
Lamivudine + tenofovir advantages:
Good virologic response when used with
efavirenz
Once-daily dosing
No food effect
NRTI + emtricitabineb advantages:
Longer half-life than lamivudine
Once-daily dosing
Truvada coformulation
NNRTI class advantages:
Established backbone of combination
antiretroviral therapy
Zidovudine + lamivudinea disadvantages:
Bone marrow suppression and GI intolerance
with zidovudine
Lamivudine + tenofovir disadvantages:
Some reports of renal impairment with tenofovir
Interactions with atazanavir and didanosine
NRTI + emtricitabineb disadvantages:
Less experience than lamivudine
NNRTI class disadvantages:
Rare but serious cases of lactic acidosis with
hepatic steatosis reported with most NRTIs
PI-based regimen Lopinavir/ritonavir  Lopinavir/ritonavirc advantages:
Potent antiretroviral activity
Potential for once-daily dosing in treatment-
naïve patients
No food restriction with oral tablet formulation
PI class advantages:
Save NNRTI for future use
Longest prospective study data, including data
on survival benefit
Lopinavir/ritonavirc disadvantages:
GI intolerance
Hyperlipidemia
Preliminary data show lower drug exposure in
pregnant women
PI class disadvantages:
Metabolic complications—fat malnutrition,
dyslipidemia, insulin resistance
Potential for drug interactions with CYP3A4
inhibitors and substrates
+ lamivudine or emtricitabine
+ zidovudine
Zidovudine + lamivudinea advantages:
Most extensive and favorable virologic
experience
Ease of dosing (coformulation)
No food effect
Lamivudine has minimal side effects
NRTI + emtricitabineb advantages:
Longer half-life than lamivudine
Once-daily dosing
Truvada coformulation
NNRTI class advantages:
Established backbone of combination
antiretroviral therapy
Zidovudine + lamivudinea disadvantages:
Bone marrow suppression with zidovudine
GI intolerance
NRTI + emtricitabineb disadvantages:
Less experience than lamivudine
NNRTI class disadvantages:
Rare but serious cases of lactic acidosis with
hepatic steatosis reported with most NRTIs
aZidovudine + lamivudine coformulated as Combivir; bTenofovir + emtricitabine coformulated as Truvada; cLopinavir + ritonavir coformulated as Kaletra.
CYP3A4, cytochrome P450 3A4; GI, gastrointestinal; NNRTI, nonnucleotide reverse transcriptase inhibitor; NRTI, nucleoside/nucleotide reverse transcriptase inhibitor; PI, protease inhibitor.
Table 4 | Preferred regimens for antiretroviral therapy in treatment-naïve patients (Gazzard 2005; DHSS 2006)7
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Drug resistance
Cross-resistance between drug classes has limited the treatment
options for patients who ultimately experience virologic failure to
the three main classes of antiretroviral therapy. These patients
typically experience viral rebound which ultimately leads to
immunologic failure (decreased CD4 cell count) and clinical
disease progression (Deeks et al. 2002; Ledergerber et al. 2004).
A study in a random sample of HIV-infected American adults
(receiving care during January and February 1996 and were alive
in 1998) with a viral load of >500 copies/mL estimated that the
prevalence of antiretroviral resistance to one or more drugs was
76%. The estimated prevalence of resistance ranged from 71%
for NRTIs to 41% for PIs and 25% for NNRTIs, with almost 50%
having multidrug resistance and 13% resistant to all three drug
classes (Richman et al. 2004). 
In patients with TCF the goal of treatment is to preserve immune
function and to prevent clinical progression. Current salvage
therapies for patients with TCF include the use of enfuvirtide
which acts as an entry inhibitor, and the use of mega- and giga-
HAART regimens (i.e. combining five or more drugs) (Miller et al.
2000; Fischl et al. 2003; Lazzarin et al. 2003). However, there are
a number of disadvantages with these options, including potential
safety and tolerability concerns with mega- and giga-HAART
regimens. Enfuvirtide is generally well tolerated, apart from the
high incidence of injection site reactions in 98% of patients.
However, it is expensive (approximately $US20 000 per patient
year) due to its complicated manufacturing process, and requires
twice-daily injections. 
Resistance to antiretroviral therapy is not only a problem in
treatment-experienced patients, but is also an issue in treatment-
naïve patients. Virus strains resistant to antiretroviral drugs may be
transmitted to others (Ammaranond et al. 2003). The transmission
of these drug-resistant HIV strains is associated with suboptimal
virologic response to initial antiretroviral therapy, and shortens the
time to first virologic failure in some patients (Little et al. 2002). 
A US study of 491 chronically infected treatment-naïve patients
reported that approximately 9–11% of patients were infected with
HIV strains conferring antiretroviral resistance, and this prevalence
appeared to be increasing over time (Novak et al. 2005). 
It is evident that there remains an unmet need for further
treatment options for treatment-experienced patients who have
exhausted all options and for treatment-naïve patients who are
infected with drug-resistant virus. Alternative therapies with novel
mechanisms of action, targeting alternative stages of the HIV
lifecycle, and that are effective against both wild type HIV and
strains of HIV resistant to commonly used antiretroviral drugs 
are required.
Factors contributing to drug resistance
The inconvenience and complexity of drug regimens with high pill
burdens and frequent dosing often leads to poor adherence to
therapy, and facilitates viral resistance to drug classes (Lucas 2005).
Therefore, simple regimens with low pill burdens are needed to
achieve a high degree of medication adherence and to help
prevent the selection of drug resistance. Drug tolerability, and
short-term and long-term toxicity, may also limit the duration of
treatment and influence adherence. Currently available
antiretroviral agents are associated with several, often severe,
adverse events which compromise quality of life, and potentially
impact on adherence to therapy (Table 4). These include lipid
perturbations, fat redistribution (peripheral fat wasting and central
adiposity), rash, diarrhea, nephrotoxicity, pancreatitis, peripheral
neuropathy, and bone marrow suppression. A potent antiretroviral
agent that is well tolerated, without significant short- and 
long-term side effects, and convenient would be an important
addition to the current armamentarium, and may improve patient
adherence to therapy. 
Drug interactions among antiretroviral agents and with other
concomitant medications are also challenging, and require
specific attention when prescribing medications and monitoring
patient progress. These drug interactions may lead to suboptimal
levels of antiretroviral drug and emergence of resistance, or may
lead to supraoptimal levels with a negative impact on tolerability
and side effects. It would be desirable to have novel antiretroviral
agents that are not metabolized by CYP450 to avoid
pharmacokinetic interactions with existing antiretroviral agents
(e.g. the PIs and efavirenz), and concomitant medications
frequently administered to HIV-infected individuals (e.g. macrolide
antibiotics, ketoconazole, statins, etc.).
Outcomes achieved with maraviroc in clinical
development
Maraviroc is a potent and selective antagonist of CCR5, with
broad-spectrum anti-HIV-1 activity (Dorr et al. 2005; Wood &
Armour 2005). Maraviroc is in the late stages of clinical
development, and phase IIb/III trials are ongoing (Table 5).
Reduction in viral load
A pharmacokinetic-pharmacodynamic disease model which
predicted in-vivo antiviral activity of maraviroc was used to assist
dosage selection for clinical phase IIa studies (Rosario et al. 2005).
The efficacy of maraviroc monotherapy was primarily assessed by
studies determining the reduction in viral load, and the proportion
of patients achieving a >1.0 log10 decrease in HIV-1 RNA. Level 2
evidence from two short-term, phase IIa studies showed that in
63 HIV-1-infected patients with CCR5-utilizing virus only 
(CD4 count >250 and plasma viral load >5000 copies/mL) treated
with maraviroc monotherapy for 10 days, maximum viral load
reductions ≥1.6 log10 were seen at all doses ≥100 mg twice daily
(bid) (Fätkenheuer et al. 2005; Table 6). For the once-daily (qd)
dosing regimen, mean viral load reductions at day 11 of 0.43,
1.13, and 1.35 log10 were seen for doses of 25, 100, and 300 mg,
respectively. In comparison, reductions in viral load of 0.66, 1.42,
1.45, and 1.6 were seen for patients receiving 50, 100, 150, and
300 mg bid, respectively. At doses of 100 mg bid, 150 mg bid,
and 300 mg qd/bid, all patients achieved a >1.0 log10 maximum
reduction in HIV-1 RNA (Table 6).Combination studies in vitro have shown that maraviroc is not
antagonistic to existing antiretroviral agents (Dorr et al. 2005).
Four ongoing phase II/III trials are currently determining the
efficacy and safety of maraviroc in combination with other
antiretroviral agents in both treatment-naïve and treatment-
experienced patients (Table 5). An ongoing phase III study in
treatment-naïve patients comparing maraviroc (300 mg qd/bid) in
combination with zidovudine/lamivudine with efavirenz in
combination with zidovudine/lamivudine demonstrated that after
16 weeks of treatment significantly more patients receiving
maraviroc qd had detectable viral loads compared with those
receiving maraviroc bid or efavirenz (Anon. 2005f). Consequently,
the Data Safety Monitoring Board (DSMB) recommended the
discontinuation of the once-daily dose arm in this study.
Rebound of viral load
In two short-term (10 day) monotherapy studies viral load rebound
was not immediate after discontinuation of maraviroc therapy on
day 11 (Fätkenheuer et al. 2005). This delay in viral rebound suggests
that maraviroc may provide prolonged viral suppression which may
be related to slow dissociation of the compound from the receptor. 
Occupancy of the CCR5 receptor was determined by a macrophage
inflammatory protein (MIP)-1-beta internalization assay. This assay
demonstrated that CCR5 occupancy remained at >60% 5 days after
discontinuation of maraviroc. A delay in viral rebound may be due to
the prolonged occupancy of CCR5 by maraviroc, and its slow rate
of dissociation (Fätkenheuer et al. 2005; Pullen et al. 2006). 
Selectivity
In vitro, maraviroc was inactive against laboratory-adapted HIV-1
isolates which utilize CXCR4 as a coreceptor, indicating that the
antiviral mechanism of maraviroc is exclusively CCR5-mediated.
It also had no significant activity against a range of
pharmacologically relevant enzymes, ion channels, and receptors,
indicating the potential for a safe clinical profile (Dorr et al. 2005). 
Resistance
In-vitro studies have shown that maraviroc is active against viruses
resistant to existing antiretroviral agents, and that resistance to
maraviroc is difficult to generate (Dorr et al. 2005). Limited evidence
in abstract form suggests that there is no cross-resistance in vitro
and in vitro [phytohemoagglutinin (PHA)-stimulated peripheral blood
lymphocytes] between maraviroc and other entry inhibitors (Westby
et al. 2005a,b; Mosley et al. 2006). Maraviroc-resistant HIV-1 variants
remained susceptible to the CCR5 antagonist aplaviroc, and to the
fusion inhibitor enfuvirtide (Westby et al. 2005a; Mosley et al. 2006). 
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ART regimen Study design Patient population Comparator Treatment duration
Maraviroc 300 mg bid +
Combivira bid 
Multicenter (worldwide),
randomized, double-blindb
HIV-1-infected (HIV-RNA
>2000 copies/mL)
Treatment-naïve adults
(1071 patients)
Efavirenz (600 mg qd)
+ Combivira bid
96 weeks, may be extended for
an additional 3 years
Maraviroc 150 mg qd + OBT
Maraviroc 150 mg bid + OBT
Placebo + OBT
Multicenter (Europe and
Australia, extended to US
and Canada), randomized,
double-blind
HIV-1-infected (HIV-RNA
>5000 copies/mL)
Treatment-experienced adults
failing current regimen
Infected exclusively with
CCR5-tropic virus
(500 patients)
Placebo  48 weeks, may be extended for an
additional year
Maraviroc 150 mg qd + OBT
Maraviroc 150 mg bid + OBT
Placebo + OBT
Multicenter (US and Canada),
randomized, double-blind
HIV-1-infected (HIV-RNA
>5000 copies/mL)
Treatment-experienced adults
failing current regimen
Infected exclusively with
CCR5-tropic virus
(500 patients)
Placebo  48 weeks, may be extended for an
additional year
Maraviroc 150 mg qd + OBT
Maraviroc 150 mg bid + OBT
Placebo + OBT
Multicenter (worldwide),
randomized, double-blind
HIV-1-infected (HIV-RNA
>5000 copies/mL)
Treatment-experienced adults
failing current regimen
Not exclusively infected with
CCR5-tropic virus
(192 patients)
Placebo 48  weeks
aZidovudine + lamivudine coformulated as Combivir. 
bThe maraviroc 300 mg qd + Combivir bid arm was discontinued by the Data Safety Monitoring Board for failure to meet preset criteria versus the comparator.
ART, antiretroviral therapy; bid, twice daily; HIV, human immunodeficiency syndrome; OBT, optimized background therapy (3–6 drugs based on treatment history and resistance testing); qd, once daily.
Table 5 | Ongoing phase II/III clinical trials with maraviroc (http://www.clinicaltrials.gov, May 2006)9
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Modeling studies demonstrate that the CCR5 antagonists bind in
a similar pocket of the CCR5 receptor within the transmembrane
region (Westby et al. 2005b). The authors proposed that these
compounds may hold the receptor in different conformations,
thereby inhibiting entry of maraviroc-resistant variants.
Data from two phase II studies in 62 CCR5-tropic, HIV-infected
patients treated with maraviroc for 10 days demonstrated that at
day 11 CXCR4-tropic variants were detected in two patients
(Westby et al. 2006). Clonal analysis suggested that this was
probably due to the outgrowth of a pretreatment CXCR4-tropic
reservoir, and not due to coreceptor switching under selective
pressure from maraviroc.
One patient harboring virus with a dual-tropic phenotype 
(virus which can use CCR5 or CXCR4 to enter CD4 cells), which
was an exclusion criterion for the phase IIa clinical study, was
inadvertently enrolled. Despite receiving maraviroc 100 mg bid
for 11 days, and CCR5 saturation and maraviroc plasma
concentrations within the normal range of responding patients,
the patient experienced no drop in viral load from baseline. 
At baseline and following cessation of maraviroc treatment, 
the R5 variant was dominant, suggesting a reversible
predominance of CXCR4-utilizing virus in dual-tropic patients
(Westby et al. 2004).
Recent data from a trial in 186 patients of whom 167 were
dual-tropic showed that although viral load did not differ
significantly following 24 weeks’ treatment with maraviroc 150 mg
once or twice daily or placebo (mean viral load reductions 
of 0.91, 0.97, and 1.2 log10, respectively), the mean increase in
CD4 cell count was greater following maraviroc treatment
compared with placebo (60 and 62 cells/L with 150 mg once or
twice daily vs 35 cells/L) (Mayer et al. 2006).
Safety and tolerability
Evidence from a combination of five phase I/IIa double-blind,
placebo-controlled, multiple-dose studies with maraviroc alone,
and one drug–drug interaction study with oral contraceptives, in a
total of 195 individuals including 66 HIV-infected patients have
demonstrated that maraviroc is well tolerated at doses up to 
300 mg twice daily (McHale et al. 2005). Five of these studies were
of 7 to 10 days’ duration including dosing at the maximum dose of
1200 mg once daily; to date, published results from one safety
study conducted for 28 days at the highest proposed clinical dose
of 300 mg twice daily are available (Russell et al. 2003; McHale et
al. 2005). No serious adverse events were reported and the
adverse event profile was similar to placebo (Table 7).
Cardiovascular effects 
Observations of QT prolongation in healthy volunteers with 
SCH-C, a CCR5 antagonist developed by Schering-Plough, led to
the termination of its development (Este 2002; Westby & van der
Ryst 2005). QT prolongation can lead to the development of
cardiac arrhythmias. Therefore, the effect of maraviroc on this
clinical parameter was studied.
Preclinical studies and a clinical study in healthy subjects have
demonstrated that single doses of maraviroc (100, 300, and 
900 mg) have no clinically significant effect on the QTc interval
(Davis et al. 2005; Mansfield et al. 2005). In addition, reported
phase I/IIa clinical trials have not demonstrated any evidence of
clinically relevant prolongation of QTcF (McHale et al. 2005). 
Postural hypotension was the dose-limiting adverse event in
phase I trials, and occurred at rates in excess of placebo only at
doses of ≥600 mg. Phase I/IIa data from six studies reported a
Patient
population
Study design Treatment
group
Mean reduction in HIV-1 RNA,
log10 copies/mL (range) 
Number of patients with >1.0 log10 decrease 
in HIV-1 RNA/total number of patients 
Day 11 Nadir Day 11 Nadir
Asymptomatic 
HIV-infected
patients with
CCR5-tropic virus
Two 10-day
studies
Phase IIa,
randomized,
placebo-controlled
Maraviroc 
25 mg qd
50 mg bid
100 mg qd
100 mg bid
150 mg bid
150 mg bid (fed)
300 mg qd
300 mg bid
Placebo (study 1)
Placebo (study 2)
–0.43 (–1.08, 0.02)
–0.66a (–1.37, 0.40)
–1.13 (–1.70, –0.43)
–1.42a (–1.84, –1.04)
–1.45 (–1.71, –0.90)
–1.34 (–1.79, –0.51)
–1.35 (–1.62, –0.95)
–1.60 (–2.42, –0.78)
0.02 (–0.45, 0.56)
0.09 (–0.20, 0.27)
–0.59 (–1.10, 0.02)
–0.86 (–1.37, –0.14)
–1.25 (–1.70, –0.61)
–1.68 (–2.10, –1.37)
–1.77 (–2.16, –1.43)
–1.74 (–2.09, –1.13)
–1.60 (–2.08, –1.14)
–1.84 (–2.42, –1.49)
–0.32 (–0.63, 0.11)
–0.32 (–0.63, 0.11)
1/8
4/8
5/8
7/7
7/8
7/8
7/8
7/8
0
0
1/8
5/8
6/8
7/7
8/8
8/8
8/8
8/8
0
0
aFed and fasted.
bid, twice daily; HIV human immunodeficiency syndrome; qd, once daily.
Table 6 | Reduction in viral load with maraviroc monotherapy [Reprinted by permission from Macmillan Publishers Ltd: Nature Medicine
(Fätkenheuer G et al. Nat Med. 2005;11:1170–1172), copyright 2005]total of two treatment-related discontinuations with maraviroc
(600 mg qd) due to postural hypotension (McHale et al. 2005). 
A small study in healthy volunteers has suggested that maraviroc
(900 mg, three times greater than the single dose suggested for
clinical use) has a mild vasodilatatory effect, reducing systemic
vascular resistance (Russell et al. 2005). 
Liver toxicity
Phase I and IIa safety data from six multiple-dose clinical studies
(195 individuals including 66 HIV-infected patients) reported 
that clinically significant increases in liver function tests occurred
in seven individuals at varying doses of maraviroc with no 
clear frequency or dose relationship (McHale et al. 2005). Four
subjects had >3 x upper limit of normal (ULN) transaminases 
and three subjects had >1.25 to <2 x ULN bilirubin only. Mild 
to moderate elevations in creatinine (<2 x ULN) were observed 
in one study at doses of 1200 mg once daily. In addition, a
pharmacokinetic crossover study in 12 healthy volunteers
showed that maraviroc in combination with the PIs tipranavir
(500 mg bid) plus ritonavir (200 mg bid) elevated alanine
aminotransferase (ALT) or aspartate aminotransferase (AST) in
five subjects after 8 days of dosing (Abel et al. 2005) which
resolved after cessation of treatment. Four of these increases in
transaminases were rated as grade 1 or 2 elevations, and one
was a grade 3 change (>3 to <5 x ULN).
A single case of severe, possibly drug-related hepatotoxicity, 
with a rash, has been reported in the phase IIb/III clinical trials in 
a treatment-naïve patient after receiving five doses of maraviroc
(300 mg qd) in combination with zidovudine and lamivudine
(Anon. 2005a,b; Mayer 2005). The case is highly complex with
several hepatotoxic drugs being administered prior to maraviroc,
or initiated after discontinuation of blinded study drug (maraviroc)
due to severe hepatotoxicity. The DSMB concluded that other
potentially hepatotoxic medications administered during this
episode, including isoniazid, cotrimoxazole, Combivir,
acetaminophen, and Kaletra, appeared to be more likely
associated with the observed hepatotoxicity, but could not rule
out that maraviroc may have contributed to the event.
Food and drug interactions
Food had no effect on the absorption of maraviroc in healthy
volunteers (Abel et al. 2003a), or the efficacy of 10-day maraviroc
monotherapy in HIV-infected patients (Fätkenheuer et al. 2005).
Therefore, it is unlikely that food restrictions will be required with
the administration of maraviroc in clinical practice.
Maraviroc is a substrate for CYP3A4 (cytochrome P450 3A4) 
but does not inhibit or induce any of the major P450 isoenzymes
(Abel et al. 2003b, 2004a). In-vitro studies in caco-2 cells and 
in vivo studies in P-glycoprotein (Pgp) knockout mice suggest that 
it is also a substrate of Pgp (Walker et al. 2005). Several drug
interaction studies in healthy volunteers have determined the
effect of CYP3A4 inhibitors and inducers on maraviroc
pharmacokinetics (Abel 2004b; Jenkins et al. 2004; Muirhead 
et al. 2004a,b; Russell et al. 2004). A study in HIV-infected
patients showed that the plasma concentration [area under 
the plasma concentration time curve (AUC)] of a single dose of
maraviroc 300 mg was reduced by 50% when administered 
with efavirenz 600 mg once daily. The maximum plasma
concentration (Cmax) was increased 1.8-fold in combination with
Kaletra 400 mg twice daily (Muirhead et al. 2005).
A pharmacokinetic crossover study in 12 healthy volunteers over
8 days showed that the CYP3A4 inducer, tipranavir (500 mg bid),
and the CYP3A4 inhibitor, ritonavir (200 mg bid) when dosed
together with maraviroc did not have a significant impact on
maraviroc (150 mg bid) drug concentrations, indicating that no
dose adjustments are required when maraviroc is given with
tipranavir 500 mg/ritonavir 200 mg twice daily (Abel et al. 2005). 
Resource utilization
The treatment of HIV infection is challenging and many patients
develop resistance to some or all classes of antiretroviral agents
currently available. An antiretroviral agent that targets an
alternative stage in the lifecycle of HIV with optimal reductions in
viral load, and good tolerability with few short- and long-term
toxicities, would have a significant impact on the prognosis of
treatment-experienced patients. 
The future use of maraviroc in the treatment of HIV infection will
depend on the outcome of phase IIb/III trials, and confirmation of
the effect of the drug on liver function. There is no economic
evidence for the use of maraviroc in the treatment of HIV.
However, it is anticipated that clinical screening tests for CCR5
viral tropism may require additional resources. This increased
cost will have to be offset by other clinical benefits.
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Adverse event, n (%) Maraviroc dose
Placebo
(n=111)
≤150 mg
(n=109)
300 mg
(n=50)
600–1200 mg
(n=61)
Headache 17 (15) 19 (17) 12 (24) 18 (30)
Dizziness 7 (6) 8 (7) 5 (10) 27 (44)
Nausea 6 (5) 1 (1) 6 (12) 16 (26)
Asthenia 8 (7) 5 (5) 3 (6) 16 (26)
Flatulence 6 (5) 3 (3) 7 (14) 8 (13)
Rhinitis 1 (1) 2 (2) 2 (4) 14 (23)
Postural hypotension 1 (1) 0 (0) 0 (0) 14 (23)
Abnormal vision 2 (2) 1 (1) 1 (2) 12 (20)
Conjunctivitis 0 (0) 0 (0) 0 (0) 14 (23)
Somnolence 3 (3) 0 (0) 0 (0) 12 (20)
Abdominal pain 3 (3) 1 (1) 2 (4) 7 (11)
Shading indicates highest proposed clinical dose. 
Table 7 | Most frequent treatment-related adverse events
reported with maraviroc (McHale et al. 2005)11
Maraviroc | proof of concept review
Core Evidence 2007;2(1)
Patient group/population
Maraviroc is in the late stages of clinical development. Data from
phase II/III studies determining its virologic effect compared with
existing regimens are not yet available. However, it is likely that
maraviroc may be used in combination with other antiretroviral
drugs in both treatment-experienced and treatment-naïve patients. 
Initially, maraviroc may be beneficial in combination with other
antiretroviral agents to treat patients infected with virus resistant
to other drug classes. However, in treatment-naïve patients with
and without drug-resistant virus, it is likely that maraviroc will
need to demonstrate an increase in the time to virologic or
immunologic failure, delayed onset of new AIDS-defining events,
increased life expectancy compared to current gold standard
regimens, or fewer short- or long-term toxicities to generate
widespread use in this patient population.
The epidemiology of R5 and X4-tropic HIV virus is important to
understand what proportion of patients may benefit from a CCR5
antagonist. A cross-sectional analysis in which 979 antiretroviral-
naïve individuals initiating triple combination therapy were
phenotyped found that 81.8% harbored R5 HIV variants, 18.1%
harbored R5/X4 variants and only one individual (0.1%) harbored
exclusively X4 variants (Brumme et al. 2005). Patients harboring
R5/X4 variants had significantly higher plasma viral loads and
lower CD4 cell counts (P<0.0001), and were more likely to have an
AIDS-defining illness before therapy initiation compared with
those patients with exclusively R5 variants (Brumme et al. 2005).
Maraviroc prevents R5 HIV from infecting otherwise healthy CD4
cells. The CCR5-tropic variant of HIV is common in the early
stages of HIV infection, so maraviroc may be most useful in acute
and early infection. CCR5 inhibitors are unlikely to be of benefit to
patients harboring X4 viruses as the predominant or minority
variant. Therefore, the effectiveness and safety of the use of
maraviroc in HIV-infected patients who do not exclusively harbor
CCR5-tropic virus needs to be verified. Preliminary evidence
indicates that although maraviroc does not reduce viral load in
dual-tropic patients, CD4 counts are increased significantly after
24 weeks (Mayer et al. 2006).
Clinical potential
Preliminary evidence indicates that maraviroc is likely to provide an
alternative therapy for treatment-experienced patients, and for
treatment-naïve patients who are newly infected with drug-resistant
virus. However, improvements in efficacy or short- and long-term
side effects for maraviroc compared with currently available
regimens in treatment-naïve patients could positively impact on its
use in this patient population provided that its use does not promote
the selection of X4 HIV and more rapid disease progression. 
Approximately 50–60% of treatment-experienced patients and
80–85% of treatment-naïve patients are infected with the CCR5-
tropic virus only. A viral tropism test (Monogram Biosciences, 
San Francisco, CA, USA) is available to determine the probability of
successful treatment, but the cost and turnaround time (3–5 weeks)
may serve as a barrier to the use of maraviroc and other CCR5
antagonists. The availability of a CXCR4 antagonist, which could
be coadministered with the CCR5 antagonists, may alleviate the
need for this test.
In-vitro evidence suggests that maraviroc is active against 
HIV resistant to current classes of antiretroviral agents. Although
it has not been shown in vivo, it may be expected that HIV will
develop resistance to CCR5 antagonists as with other
antiretroviral agents. It has been suggested that there are three
ways in which resistance may develop (Leonard & Roy 2006).
Firstly, selective inhibition of CCR5-tropic virus with CCR5
antagonist therapy may lead to an increased rate of emergence of
CXCR4 variants in patients who harbor both the R5 and X4 virus,
and vice versa. Although this has not been observed in vitro or 
in vivo during short-course monotherapy studies, the potential for
emergence of X4 HIV-1 variants during maraviroc therapy, and the
ability of the virus to adapt to using a different coreceptor or to
gain the ability to use the CCR5 coreceptor despite the presence
of antagonist will require close monitoring during clinical trials. 
In-vitro studies have demonstrated that it is difficult to select
maraviroc-resistant virus. In-vitro and short-course monotherapy
studies suggest that the maraviroc-resistant virus appears to gain
the ability to recognize and use the maraviroc-bound CCR5
coreceptor complex (Mosley et al. 2006).
Maraviroc has a long half-life and has potent activity against R5
HIV-1  in vitro. Short-term monotherapy studies in HIV-infected
patients have provided evidence for reductions in viral load 
with maraviroc. The impact of maraviroc on duration of viral
suppression, disease progression to AIDS, and survival has not
yet been reported.
The doses of maraviroc studied in phase IIb/III trials have
demonstrated good short-term tolerability. A case of serious
drug-related hepatotoxicity has been reported in phase IIb/III
studies with maraviroc. Although maraviroc was unlikely to be the
cause of hepatotoxicity it could not be ruled out. The DSMB
concluded that other potentially hepatotoxic medications
administered during this episode were the more likely cause for
the hepatotoxicity. Because the clinical development of aplaviroc
was discontinued due to hepatotoxicity, there remains concern
that hepatotoxicity may be a CCR5 antagonist class effect 
(Anon. 2005d). However, in the limited published data available to
date, there have been no reports of hepatotoxicity with vicriviroc 
(SCH-D). The DSMB recommended that all phase IIb/III clinical
studies in antiretroviral-naïve and antiretroviral-experienced
patients with maraviroc continued as currently designed (Anon.
2005e). Despite the early encouraging results with maraviroc and
vicriviroc, further data from long-term studies in larger patient
populations are required to confirm the safety profile of maraviroc. 
The short-term lack of toxicity and low pill burden (i.e. single-pill
dosing) with maraviroc monotherapy imply that it would not be
expected to add to the existing burden with current regimens, and
may potentially result in fewer discontinuations, and improved
adherence to therapy if used in place of potentially more toxic
agents. Maraviroc is metabolized by CYP3A4, therefore doseadjustments will be required when it is used in combination with
commonly used antiretroviral agents such as the PI ritonavir (an
inhibitor of CYP3A4) and the NNRTI efavirenz (CYP3A4 inducer).
In summary, maraviroc meets an unmet need for a well-tolerated
drug that reduces viral load and targets a novel early stage in the
HIV lifecycle, without preexisting class resistance. Long-term
clinical studies in combination with other antiretroviral drugs are
awaited to determine what clinical benefits (safety and resistance
profile and long-term antiviral effect) may be associated with the
use of maraviroc.
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